Study to Enroll 600 Patients and Evaluate Real-World Clinical and Patient Reported Outcomes Across All Brain Tumor Types
– First Patient Enrolled by Vidant Health in Greenville, N.C.
Seven Startups Selected from Global Field, Matched with Three Leading U.S. Healthcare Payers for Support and Funding
The funding will advance R&D on the JAZBI™ bioresorbable implant system. The award also provides access to the NSW healthcare system resources and critical insights from NSW Health medical devices expert panel.
Cala Health announced that it had received FDA breakthrough device designation for its Cala Trio treatment for action tremors in people with Parkinson’s disease.
Inc.’s third annual Female Founders 100 celebrates the success stories and best business advice of the game-changing women of 2020.
Alessa’s Biolen implant is designed to deliver an anti-androgen drug to the target tissue in the prostate.
Along with funds announced a few months back, this brings the round’s total to $20.8 million.
The 900-participant study uses learnings from Apple’s Tueo Health acquisition and could inform the development of a digital biomarker for […]
Obsidio is a Rosenman Innovator company. From the press release. Obsidio, Inc., a pre-clinical stage medical materials developer, today announced […]
Deep Blue is a Rosenman Innovator company. From the press release. Deep Blue Medical Advances today announced it has received […]